Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 1, 2013, Pages 77-82

  Ha, Huan T ^a   Griffith, Kent A ^b   Zalupski, Mark M ^c   Schuetze, Scott M ^c   Thomas, Dafydd G ^c   Lucas, David R ^c   Baker, Laurence H ^c   Chugh, Rashmi ^c  

^a Moses Cone Regional Cancer Center   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

bone sarcoma; cetuximab; clinical trial; EGFR; epidermal growth factor receptor; sarcoma; soft tissue sarcoma

Indexed keywords

CETUXIMAB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN;

ACNE; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DNA EXTRACTION; DRUG EFFICACY; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HUMAN; HUMAN TISSUE; ILEUS; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; TREATMENT RESPONSE; VERTIGO; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SARCOMA; SOFT TISSUE NEOPLASMS; YOUNG ADULT;

EID: 84872917965     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31823a4970     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249
2. Hartmann JT. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs. 2007;18:245-254 (Pubitemid 46192976)
3. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987;5:840-850 (Pubitemid 17119988)
4. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11:1269-1275 (Pubitemid 23199129)
5. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276-1285 (Pubitemid 23199130)
6. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755-2763 (Pubitemid 47123184)
7. Kersting C, Packeisen J, Leidinger B, et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol. 2006;59:585-590 (Pubitemid 43886041)
8. Beech D, Pollock RE, Tsan R, et al. Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells. Int J Oncol. 1998;12:329-336 (Pubitemid 28064857)
9. Yang JL, Hannan MT, Russell PJ, et al. Expression of HER1/
10. EGFR protein in human soft tissue sarcomas. Eur J Surg Oncol. 2006;32:466-468
11. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(suppl 4):S3-S8 (Pubitemid 32938123)
12. Li H, Velasco-Miguel S, Vass WC, et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002;62: 4507-4513 (Pubitemid 34827315)
13. Benini S, Manara MC, Cerisano V, et al. Contribution of MEK/
14. MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. Int J Cancer. 2004;108:358-366
15. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: A gene expression study. Lancet. 2002;359:1301-1307 (Pubitemid 34310636)
16. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res. 2005;65:9226-9235 (Pubitemid 41507988)
17. Gusterson B, Cowley G, McIlhinney J, et al. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer. 1985;36:689-693 (Pubitemid 16211472)
18. Bode B, Frigerio S, Behnke S, et al. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol. 2006;19:541-547
19. Sato O, Wada T, Kawai A, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: A clinicopathologic study of 281 cases. Cancer. 2005;103: 1881-1890 (Pubitemid 40563261)
20. De Giovanni C, Landuzzi L, Frabetti F, et al. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res. 1996;56: 3898-3901 (Pubitemid 26284736)
21. DeClue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest. 2000;105: 1233-1241 (Pubitemid 30266076)
22. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351: 337-345 (Pubitemid 38944402)
23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578 (Pubitemid 43209104)
24. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810 (Pubitemid 46211358)
25. Kies MS, Ghebremichael MS, Katz TL, et al. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2007;25(18 suppl):6024s. 24. Tawbi H, Thomas D, Lucas DR, et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist. 2008;13:459-466
26. Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005;103:830-838 (Pubitemid 40216413)
27. Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods? Eur J Cancer. 2005;41:1383-1392 (Pubitemid 40826461)
28. Albritton KH, Rankin C, Coffin M, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol. 2006;24(18 suppl):524s. 28. Ray-Coquard I, Le Cesne A, Whelan JS, et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist. 2008;13:467-473
29. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res. 1989;49:4682-4689 (Pubitemid 19213607)
30. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379 (Pubitemid 351171687)
31. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634
32. Yoo J, Robinson RA. H-ras and K-ras mutations in soft tissue sarcoma: Comparative studies of sarcomas from Korean and American patients. Cancer. 1999;86:58-63 (Pubitemid 29293377)
33. Antillon-Klussmann F, Garcia-Delgado M, Villa-Elizaga I, et al. Mutational activation of ras genes is absent in pediatric osteosarcoma. Cancer Genet Cytogenet. 1995;79:49-53
34. Hall KL, Teneriello MG, Taylor RR, et al. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol. 1997;65:330-335 (Pubitemid 27216950)
35. Wilke W, Maillet M, Robinson R. H-ras-1 point mutations in soft tissue sarcomas. Mod Pathol. 1993;6:129-132
36. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006; 12:5064-5073 (Pubitemid 44453332)
37. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350: 2129-2139 (Pubitemid 38637993)
38. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500 (Pubitemid 38720929)
39. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237 (Pubitemid 47325606)
40. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743 (Pubitemid 46021510)
41. Ren W, Korchin B, Zhu QS, et al. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin Cancer Res. 2008;14:2785-2795